https://scholars.lib.ntu.edu.tw/handle/123456789/470842
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHAO-CHI HO | en_US |
dc.contributor.author | SUNG-HSIN KUO | en_US |
dc.contributor.author | PEI-HSIN HUANG | en_US |
dc.contributor.author | Huang H.-Y. | en_US |
dc.contributor.author | CHIH-HSIN YANG | en_US |
dc.contributor.author | PAN-CHYR YANG | en_US |
dc.creator | Ho C.-C.;Kuo S.-H.;Pei-Hsin Huang;Huang H.-Y.;Yang C.-H.;Yang P.-C. | - |
dc.date.accessioned | 2020-03-05T08:16:43Z | - |
dc.date.available | 2020-03-05T08:16:43Z | - |
dc.date.issued | 2008 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-37549016730&doi=10.1016%2fj.lungcan.2007.07.024&partnerID=40&md5=d99a470b3e0a74fe666fbc943d01b80a | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/470842 | - |
dc.description.abstract | Caveolin-1 was up-regulated in different drug-resistant cancer cell lines and was suggested to confer drug resistance by different mechanisms. However, the relation of caveolin-1 expression and the clinical response to chemotherapy and prognosis in non-small cell lung cancer (NSCLC) remains unknown. Total 73 NSCLC (stages IIIB and IV) patients who received gemcitabine-based chemotherapy and also had tumour specimens available before treatment were assessed for caveolin-1 expression using immunohistochemistry. Immunoreactivity of caveolin-1 was correlated with the response to chemotherapy, the clinicopathologic features, and the progression-free survival (PFS) and overall survival (OS) of all patients. Positive caveolin-1 immunostaining was found in 12 (16.4%) of the 73 patients. Eight of the twelve had disease progression and the other four patients remained stable after chemotherapy. Patients with caveolin-1 expression had a significantly lower response rate (complete or partial response, 0% versus 37.7%; P = 0.01) and a poor PFS and OS (median survival time: PFS, 4.6 months versus 6.1 months, P = 0.005; OS, 7.0 months versus 14 months, P < 0.001) than those without caveolin-1 expression. Moreover, multivariate analyses indicated that caveolin-1 positivity was an independent prognostic factor for disease-free survival (DFS) (P = 0.003) and OS (P = 0.008), respectively. Caveolin-1 expression significantly correlated with drug resistance and a poor prognosis in advanced NSCLC patients treated with gemcitabine-based chemotherapy. ? 2007 Elsevier Ireland Ltd. All rights reserved. | - |
dc.relation.ispartof | Lung Cancer | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | caveolin 1; cisplatin; epirubicin; gemcitabine; adult; advanced cancer; aged; article; cancer combination chemotherapy; cancer survival; combination chemotherapy; drug response; female; human; human tissue; immunohistochemistry; lung non small cell cancer; major clinical study; male; monotherapy; multiple cycle treatment; overall survival; priority journal; prognosis; protein expression; treatment outcome; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis | - |
dc.title | Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.lungcan.2007.07.024 | - |
dc.identifier.pmid | 17850918 | - |
dc.identifier.scopus | 2-s2.0-37549016730 | - |
dc.relation.pages | 105-110 | - |
dc.relation.journalvolume | 59 | - |
dc.relation.journalissue | 1 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Radiation Oncology-NTUCC | - |
crisitem.author.dept | Division of Radiation Oncology | - |
crisitem.author.dept | Pathology | - |
crisitem.author.dept | Pathology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Pharmacy | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Biomedical Electronics and Bioinformatics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-8156-2413 | - |
crisitem.author.orcid | 0000-0003-0054-887X | - |
crisitem.author.orcid | 0000-0002-2414-1487 | - |
crisitem.author.orcid | 0000-0002-5586-5138 | - |
crisitem.author.orcid | 0000-0001-6330-6048 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | Oncology-NTUH | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Electrical Engineering and Computer Science | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。